Bilateral Acute Depigmentation of Iris (BADI) and Bilateral Acute Iris Transillumination (BAIT)-An Update
PDF
Cite
Share
Request
Invited Review
VOLUME: 52 ISSUE: 5
P: 342 - 347
October 2022

Bilateral Acute Depigmentation of Iris (BADI) and Bilateral Acute Iris Transillumination (BAIT)-An Update

Turk J Ophthalmol 2022;52(5):342-347
1. İstanbul University, İstanbul Faculty of Medicine, Department of Ophthalmology, İstanbul, Turkey
2. Eye Protection Foundation Bayrampaşa Eye Hospital, İstanbul, Turkey
3. University of Health Sciences Turkey, Beyoğlu Eye Training and Research Hospital, İstanbul, Turkey
No information available.
No information available
Received Date: 20.09.2022
Accepted Date: 30.09.2022
Publish Date: 28.10.2022
PDF
Cite
Share
Request

ABSTRACT

Bilateral acute depigmentation of the iris (BADI) and bilateral acute iris transillumination (BAIT) are relatively new clinical entities characterized by acute pigment dispersion from the iris stroma or iris pigment epithelium, respectively. While BADI presents with diffuse or geographic areas of iris stromal depigmentation without transillumination, BAIT cases typically develop diffuse iris transillumination and mydriatic atonic pupils. Prolonged pigment dispersion and ocular hypertension are more common in BAIT. Although the exact etiopathogenesis is still unknown, moxifloxacin toxicity appears to be a probable/likely cause. The underlying cause of BADI or BAIT in patients who were not exposed to fluoroquinolone antibiotics remains unexplained. Systemic viral infections, including coronavirus disease 2019, may be the triggering event in several cases.

Keywords:
Bilateral acute depigmentation of the iris, bilateral acute iris transillumination, ocular hypertension, moxifloxacin, pigment dispersion

Introduction

Bilateral acute depigmentation of the iris (BADI) and bilateral acute iris transillumination (BAIT) are peculiar pigment dispersion syndromes first described in the early 2000s.1,2 While these two entities have distinct clinical phenotypes and disease course, they may belong to the same spectrum, although the etiopathogenesis remains unclear.

Conclusion

Although BADI and BAIT have the common feature of sudden-onset symptomatic pigment dispersion in both eyes, iris stromal depigmentation with a benign course is seen in BADI, whereas BAIT is characterized by iris pigment epithelial depigmentation and has a more protracted course with persistent mydriasis and potentially severe OHT. There are recent reports of atypical unilateral cases as well as reports of both phenotypes being found in the same eye or both eyes of the same patient. Oral moxifloxacin intake has been held responsible for several cases of BAIT, and there are recent reports of unilateral BAIT-like syndrome after intracameral moxifloxacin injection. Yet there are still reports of patients without any history of antibiotic treatment, including those who developed BADI or BAIT following COVID-19 infection. An increased awareness of the presentation patterns of BADI and BAIT will ensure timely diagnosis and avoid unnecessary investigations. Ophthalmologists should remain vigilant when history-taking to avoid missing a history of past or present systemic illness and medication use which might be the trigger of acute pigment dispersion. Fluoroquinolone antibiotics should be avoided in patients with a history of BADI or BAIT, as a rechallenge may potentially exacerbate pigment dispersion.

References

1
Tugal-Tutkun I, Urgancioglu M. Bilateral acute depigmentation of the Iris. Graefes Arch Clin Exp Ophthalmol. 2006;244:742-746.
2
Bringas Calvo R, Iglesias Cortiñas D. Acute and bilateral uveitis secondary to moxifloxacin. Arch Soc Esp Oftalmol. 2004;79:357-359.
3
Tugal-Tutkun I, Araz B, Taskapili M, Akova YA, Yalniz-Akkaya Z, Berker N, Emre S, Gezer A. Bilateral acute depigmentation of the iris: report of 26 new cases and four-year follow-up of two patients. Ophthalmology. 2009;116:1552-1557.
4
Barraquer F, Mejía LF. Bilateral acute depigmentation of the iris. First report on the American continent and 5 years follow-up of two patients. J Emmetropia. 2012;3:118-122.
5
Langevin S, Gershkovich A, Marr BP. A case of bilateral acute depigmentation of the Iris in one of two identical twins. BMC Ophthalmol. 2020;20:13.
6
Amin R, Nabih A, Khater N. Bilateral acute depigmentation of the iris in two siblings simultaneously. Am J Ophthalmol Case Rep. 2018;10:257-260.
7
Kawali A, Mahendradas P, Shetty R. Acute depigmentation of the iris: a retrospective analysis of 22 cases. Can J Ophthalmol. 2019;54:33-39.
8
Escribano López P, González-Guijarro JJ. Bilateral Acute Depigmentation of the Iris: Findings in Anterior Segment Swept-Source Optical Coherence Tomography. Ocul Immunol Inflamm. 2019;27:1288-1292.
9
Singh S, Diwan S, Sachdev MS. Bilateral acute depigmentation of the iris in a child following exposure to insecticide spray. Indian J Ophthalmol. 2020;68:1191-1193.
10
Wefers Bettink-Remeijer M, Brouwers K, van Langenhove L, De Waard PW, Missotten TO, Martinez Ciriano JP, Van Aken E. Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin. Eye (Lond). 2009;23:2260-2262.
11
Willermain F, Deflorenne C, Bouffioux C, Janssens X, Koch P, Caspers L. Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin. Eye (Lond). 2010;24:1419-1420.
12
Tugal-Tutkun I, Onal S, Garip A, Taskapili M, Kazokoglu H, Kadayifcilar S, Kestelyn P. Bilateral acute iris transillumination. Arch Ophthalmol. 2011;129:1312-1319.
13
Tranos P, Lokovitis E, Masselos S, Kozeis N, Triantafylla M, Markomichelakis N. Bilateral acute iris transillumination following systemic administration of antibiotics. Eye (Lond). 2018;32:1190-1196.
14
Morshedi RG, Bettis DI, Moshirfar M, Vitale AT. Bilateral acute iris transillumination following systemic moxifloxacin for respiratory illness: report of two cases and review of the literature. Ocul Immunol Inflamm. 2012;20:266-272.
15
Degirmenci C, Guven Yilmaz S, Palamar M, Ates H. Bilateral acute iris transillumination: Case report. Saudi J Ophthalmol. 2016;30:122-124.
16
Yagci BA, Atas F, Kaya M, Arikan G. COVID-19 Associated Bilateral Acute Iris Transillumination. Ocul Immunol Inflamm. 2021;29:719-721.
17
Altan C, Basarir B, Kesim C. An unexpected complication in bilateral acute iris transillumination: Cystoid macular edema. Indian J Ophthalmol. 2018;66:869-871.
18
Altan C, Basarir B, Bayraktar S, Tugal-Tutkun I. Bilateral Acute Depigmentation of Iris (BADI) and Bilateral Acute Iris Transillumination (BAIT) Following Acute COVID-19 Infection. Ocul Immunol Inflamm. 2022:1-6.
19
Kreps EO, Hondeghem K, Augustinus A, Sys C, Van de Veire S, Leroy BP, Schauwvlieghe PP. Is oral moxifloxacin associated with bilateral acute iris transillumination. Is oral moxifloxacin associated with bilateral acute iris transillumination? Acta Ophthalmol. 2018;96:547-548.
20
Wey S, Flamendorf J, Sinha S, Lee D. Surgical Management of Glaucoma Secondary to Bilateral Acute Iris Transillumination: A Role for Gonioscopy-assisted Translüminal Trabeculotomy. J Ophthalmic Vis Res. 2021;16:122-126.
21
Bayraktar S, Oray M, Altan C, Basarir B, Izgi B, Tugal-Tutkun I. Long-term Results of Trabeculectomy With Mitomycin-C in Patients With Bilateral Acute Iris Transillumination. J Glaucoma. 2019;28:797-802.
22
Perone JM, Chaussard D, Hayek G. Bilateral acute iris transillumination (BAIT) syndrome: literature review. Clin Ophthalmol. 2019;13:935-943.
23
Knape RM, Sayyad FE, Davis JL. Moxifloxacin and bilateral acute iris transillumination. J Ophthalmic Inflamm Infect. 2013;3:10.
24
Peñaranda-Henao M MD, Reyes-Guanes J MS, Muñoz-Ortiz J MD, Gutiérrez NM MD, De-La-Torre A PhD. Anterior Uveitis Due to Intracameral Moxifloxacin: A Case Report. Ocul Immunol Inflamm. 2021;29:1366-1369.
25
Light JG, Falkenberry SM. Unilateral bilateral acute iris transillumination-like syndrome after intracameral moxifloxacin injection for intraoperative endophthalmitis prophylaxis. JCRS Online Case Reports. 2019;7:3-5.
26
Sánchez-Sánchez C, Puerto B, López-Caballero C, Contreras I. Unilateral acute iris depigmentation and transillumination after glaucoma surgery with mitomycin application and intracameral moxifloxacin. Am J Ophthalmol Case Rep. 2020;18:100639.
27
Zubicoa A, Echeverria-Palacios M, Mozo Cuadrado M, Compains Silva E. Unilateral acute iris transillumination like syndrome following intracameral moxifloxacin injection. Ocul Immunol Inflamm. 2022;30:318-319.
28
Gonul S, Eker S. Unilateral Acute Iris Transillumination Syndrome following Uneventful Phacoemulsification Surgery with Intracameral Moxifloxacin. Ocul Immunol Inflamm. 2021:1-4.
29
Hinkle DM. Re-assessing Evidence for Adverse Ocular Reactions Associated with Fluoroquinolones: Implications for Intracameral Use. Ocul Immunol Inflamm. 2022;30:208-209.
30
Hinkle DM, Dacey MS, Mandelcorn E, Kalyani P, Mauro J, Bates JH, Soukasian SH, Holland GN, Foster CS, Fraunfelder FT, Davis JL, Fraunfelder FW. Bilateral uveitis associated with fluoroquinolone therapy. Cutan Ocul Toxicol. 2012;31:111-116.
31
Accorinti M, Petitti L, Gaeta A, Giannini D, De Geronimo D. Viral Acute Anterior Uveitis: Clinical Signs Useful for Differential Diagnosis. Ocul Immunol Inflamm. 2021;29:1355-1362.
32
Niyadurupola N, Broadway DC. Pigment dispersion syndrome and pigmentary glaucoma--a major review. Clin Exp Ophthalmol. 2008;36:868-882.
33
Gonul S, Bozkurt B, Okudan S, Tugal-Tutkun I. Bilateral acute iris transillumination following a fumigation therapy: a village-based traditional method for the treatment of ophthalmomyiasis. Cutan Ocul Toxicol. 2015;34:80-83.
34
Yüksel M, Özdemir HB, Özdek Ş, Gürelik G. Bilateral acute Iris transillumination after COVID-19 pneumonia. Eur J Ophthalmol. 2022:11206721221113428.
35
Patnaik G, Arunkumar WV, Lagvankar M. Bilateral Acute Depigmentation of Iris (BADI) Post COVID Infection following Systemic Moxifloxacin Therapy. Ocul Immunol Inflamm. 2022:1-3.